Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors
V Gupta, P Hari, R Hoffman - … Journal of the American Society of …, 2012 - ashpublications.org
The discovery of JAK2617F mutation paved the way for the development of small molecule
inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of …
inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of …
[HTML][HTML] Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm
Tumor heterogeneity presents a challenge for inferring clonal evolution and driver gene
identification. Here, we describe a method for analyzing the cancer genome at a single-cell …
identification. Here, we describe a method for analyzing the cancer genome at a single-cell …
One thousand patients with primary myelofibrosis: the mayo clinic experience
A Tefferi, TL Lasho, T Jimma, CM Finke, N Gangat… - Mayo Clinic …, 2012 - Elsevier
Objective To share our decades of experience with primary myelofibrosis and underscore
the importance of outcomes research studies in designing clinical trials and interpreting their …
the importance of outcomes research studies in designing clinical trials and interpreting their …
Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study
Purpose Reported survival in patients with myeloproliferative neoplasms (MPNs) shows
great variation. Patients with primary myelofibrosis (PMF) have substantially reduced life …
great variation. Patients with primary myelofibrosis (PMF) have substantially reduced life …
Ruxolitinib for the treatment of myelofibrosis: its clinical potential
A Ostojic, R Vrhovac, S Verstovsek - Therapeutics and Clinical …, 2012 - Taylor & Francis
Ruxolitinib is an orally bioavailable, selective Janus kinase (JAK) 1 and 2 inhibitor approved
for the treatment of myelofibrosis (MF), a bone marrow disease in which the JAK pathway is …
for the treatment of myelofibrosis (MF), a bone marrow disease in which the JAK pathway is …
Why does my patient have thrombocytosis?
NH Sulai, A Tefferi - Hematology/Oncology Clinics, 2012 - hemonc.theclinics.com
Thrombocytosis is defined as having excess platelets in the blood. The normal platelet count
in adults ranges between 150,000 and 450,000/mL (mean Æ 2 standard deviations) …
in adults ranges between 150,000 and 450,000/mL (mean Æ 2 standard deviations) …
Advances in the management of myelofibrosis
RS Komrokji, S Verstovsek, E Padron… - Cancer Control, 2012 - journals.sagepub.com
Background Myelofibrosis (MF) is a rare and serious hematologic malignancy classified as a
Philadelphia chromosome-negative myeloproliferative neoplasm (MPN). The disease is …
Philadelphia chromosome-negative myeloproliferative neoplasm (MPN). The disease is …
Acute ST-segment elevation myocardial infarction: a rare initial presentation of previously undiagnosed essential thrombocythemia
A Singla, D Jagasia, M Garg, PA Lowry, D Stapleton - Platelets, 2012 - Taylor & Francis
Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by
hemorrhagic and thrombotic complications. We describe a rare case of ST-segment …
hemorrhagic and thrombotic complications. We describe a rare case of ST-segment …
JAK2 inhibitors in the treatment of myeloproliferative neoplasms
R Tibes, JM Bogenberger, HL Geyer… - Expert Opinion on …, 2012 - Taylor & Francis
Introduction: Dysregulation of JAK-STAT signaling is a pathogenetic hallmark of
myeloproliferative neoplasms (MPNs) arising from several distinct molecular aberrations …
myeloproliferative neoplasms (MPNs) arising from several distinct molecular aberrations …
[HTML][HTML] The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis
A Kirabo, SO Park, HL Wamsley, M Gali… - The American journal of …, 2012 - Elsevier
Philadelphia chromosome–negative myeloproliferative neoplasms, including polycythemia
vera, essential thrombocytosis, and myelofibrosis, are disorders characterized by abnormal …
vera, essential thrombocytosis, and myelofibrosis, are disorders characterized by abnormal …